Information Letter on the medicinal products Invokana® (canagliflozin) and Vokanamet® (canagliflozin, metformin) that contain canagliflozin: Risk of lower limb amputation
2016.05.02
Active substance: canagliflozin, metformin
In view of the European safety review initiated due to an increase in amputation, primarily of the toe, observed in an ongoing clinical trial with canagliflozin, the company Janssen-Cilag International N.V. is circulating information on important new safety-relevant findings.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN